Outcomes in COVID-19 varespladib studies

0 0.5 1 1.5+ All studies -120% 1 18 Improvement, Studies, Patients Relative Risk Mortality -120% 1 18 Ventilation -240% 1 18 RCTs -120% 1 18 Late -120% 1 18 Varespladib for COVID-19 c19early.org November 2025 Favorsvarespladib Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] death 1/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk All studies -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk 1 varespladib COVID-19 study c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Effect extraction pre-specified(most serious outcome) Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] 1/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk All studies -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk 1 varespladib COVID-19 mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -240% 3.40 [0.20-57.7] 2/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Late treatment -240% 3.40 [0.20-57.7] 2/15 0/3 240% higher risk All studies -240% 3.40 [0.20-57.7] 2/15 0/3 240% higher risk 1 varespladib COVID-19 mechanical ventilation result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.4 Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] death 1/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk All studies -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk 1 varespladib COVID-19 serious outcome c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Effect extraction pre-specified(most serious outcome) Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] death 1/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk All studies -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk 1 varespladib COVID-19 Randomized Controlled Trial c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Effect extraction pre-specified(most serious outcome) Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] 1/15 0/3 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Late treatment -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk All studies -120% 2.20 [0.11-44.5] 1/15 0/3 120% higher risk 1 varespladib COVID-19 RCT mortality result c19early.org November 2025 Tau​2 = 0.00, I​2 = 0.0%, p = 0.62 Favors varespladib Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STAIRS Lickteig (DB RCT) -120% 2.20 [0.11-44.5] death 1/15 0/3 Improvement, RR [CI] Treatment Control STAIRS Lickteig (DB RCT) -240% 3.40 [0.20-57.7] ventilation 2/15 0/3 STAIRS Lickteig (DB RCT) -240% 3.40 [0.20-57.7] progression 2/15 0/3 Varespladib COVID-19 outcomes c19early.org November 2025 Favors varespladib Favors control